{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:39:10Z","timestamp":1792276750141,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"am","delay-in-days":762,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012314","name":"Shinshu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17710"],"award-info":[{"award-number":["20K17710"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.hlc.2022.12.014","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T18:28:59Z","timestamp":1680719339000},"page":"836-843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses"],"prefix":"10.1016","volume":"32","author":[{"given":"Hajime","family":"Ichimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2022.12.014_bib1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2022.12.014_bib2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.108.175505","article-title":"Human embryonic stem cell-derived cardiomyocytes and cardiac repair in rodents","volume":"102","author":"van Laake","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.hlc.2022.12.014_bib3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nbt1327","article-title":"Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts","volume":"25","author":"Laflamme","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2022.12.014_bib4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nature19815","article-title":"Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts","volume":"538","author":"Shiba","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.hlc.2022.12.014_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature13233","article-title":"Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts","volume":"510","author":"Chong","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.hlc.2022.12.014_bib6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.stemcr.2019.04.005","article-title":"Human embryonic stem cell-derived cardiomyocytes regenerate the infarcted pig heart but induce ventricular tachyarrhythmias","volume":"12","author":"Romagnuolo","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.hlc.2022.12.014_bib7","first-page":"1271","article-title":"The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town","volume":"41","author":"Barnard","year":"1967","journal-title":"S\u00a0Afr Med J"},{"key":"10.1016\/j.hlc.2022.12.014_bib8","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib9","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","volume":"321","author":"Kahan","year":"1989","journal-title":"Cyclosporine. N Engl J Med"},{"key":"10.1016\/j.hlc.2022.12.014_bib10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J\u00a0Antibiot (Tokyo)"},{"key":"10.1016\/j.hlc.2022.12.014_bib11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM199410273311702","article-title":"S.\u00a0Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation","volume":"331","author":"U","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hlc.2022.12.014_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A\u00a0comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.hlc.2022.12.014_bib13","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/j.1600-6143.2006.01300.x","article-title":"Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients\u2014a large European trial","volume":"6","author":"Grimm","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00228-010-0902-6","article-title":"Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials","volume":"66","author":"Penninga","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.hlc.2022.12.014_bib15","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1161\/01.CIR.0000150332.42276.69","article-title":"Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs","volume":"110","author":"Lindenfeld","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2022.12.014_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.healun.2005.02.002","article-title":"Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients","volume":"24","author":"Eisen","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib17","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1161\/01.CIR.0000136812.90177.94","article-title":"Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial","volume":"110","author":"Keogh","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2022.12.014_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ajt.12181","article-title":"Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial","volume":"13","author":"Eisen","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.hlc.2022.12.014_bib20","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1161\/CIR.0000000000000093","article-title":"Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management","volume":"131","author":"Colvin","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2022.12.014_bib21","first-page":"486","article-title":"Successful treatment of acute humoral rejection in a heart transplant patient","volume":"11","author":"Malafa","year":"1992","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib22","first-page":"413","article-title":"Reversal of rejection-induced coronary vasculitis detected early after heart transplantation with increased immunosuppression","volume":"8","author":"Ballester","year":"1989","journal-title":"J\u00a0Heart Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.healun.2007.01.006","article-title":"Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial","volume":"26","author":"Carrier","year":"2007","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41598-020-80567-9","article-title":"Basiliximab impairs regulatory T cell (TREG) function and could affect the short-term graft acceptance in children with heart transplantation","volume":"11","author":"L\u00f3pez-Abente","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2022.12.014_bib25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.healun.2004.09.003","article-title":"Treatment of vascular rejection with rituximab in cardiac transplantation","volume":"24","author":"Garrett","year":"2005","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib26","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1111\/j.1600-6143.2007.02000.x","article-title":"Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation","volume":"7","author":"Reams","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.healun.2007.11.569","article-title":"Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use","volume":"27","author":"Das","year":"2008","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib28","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.4049\/jimmunol.157.5.1944","article-title":"Induction of \u201cinfectious\u201d tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients","volume":"157","author":"Onodera","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hlc.2022.12.014_bib29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0041-1345(98)01978-2","article-title":"Differential effect of an anti-CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts","volume":"31","author":"He","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.hlc.2022.12.014_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41232-021-00190-7","article-title":"Evaluation of immunosuppression protocols for MHC-matched allogeneic iPS cell-based transplantation using a mouse skin transplantation model","volume":"42","author":"Kamatani","year":"2022","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.hlc.2022.12.014_bib31","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fimmu.2017.01169","article-title":"Successful treatment of T cell-mediated acute rejection with delayed CTLA4-Ig in mice","volume":"8","author":"Young","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlc.2022.12.014_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/01.TP.0000158275.56248.F8","article-title":"CTLA-4 is important in maintaining long-term survival of cardiac allografts","volume":"79","author":"Chandraker","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.hlc.2022.12.014_bib33","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/ajt.15319","article-title":"Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation","volume":"19","author":"Badell","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.hlc.2022.12.014_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.hlc.2022.12.014_bib35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jacc.2017.11.047","article-title":"Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction","volume":"71","author":"Menasch\u00e9","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2022.12.014_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.950829","article-title":"Transplantation of IPSC-derived cardiomyocyte patches for ischemic cardiomyopathy","volume":"9","author":"Miyagawa","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.hlc.2022.12.014_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nbt.4162","article-title":"Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates","volume":"36","author":"Liu","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2022.12.014_bib38","doi-asserted-by":"crossref","first-page":"11883","DOI":"10.1038\/s41598-020-68373-9","article-title":"Increased predominance of the matured ventricular subtype in embryonic stem cell-derived cardiomyocytes in\u00a0vivo","volume":"10","author":"Ichimura","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2022.12.014_bib39","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/j.jaci.2009.11.014","article-title":"Transplantation immunology: solid organ and bone marrow","volume":"125","author":"Chinen","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.hlc.2022.12.014_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.stemcr.2017.07.020","article-title":"NK cell alloreactivity against KIR-ligand-mismatched HLA-haploidentical tissue derived from HLA haplotype-homozygous iPSCs","volume":"9","author":"Ichise","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.hlc.2022.12.014_bib41","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nbt0708-739","article-title":"HLA-haplotype banking and iPS cells","volume":"26","author":"Nakatsuji","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2022.12.014_bib42","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(05)67813-0","article-title":"Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching","volume":"366","author":"Taylor","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2022.12.014_bib43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.stem.2012.07.014","article-title":"Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types","volume":"11","author":"Taylor","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.hlc.2022.12.014_bib44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hlc.2022.12.014_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0352-x","article-title":"Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering","volume":"51","author":"Jang","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.hlc.2022.12.014_bib46","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.stemcr.2020.02.006","article-title":"Generation of retinal pigment epithelial cells derived from human embryonic stem cells lacking human leukocyte antigen class I and II","volume":"14","author":"Petrus-Reurer","year":"2020","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.hlc.2022.12.014_bib47","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2022.12.014_bib48","article-title":"Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy","volume":"7","author":"Mattapally","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.hlc.2022.12.014_bib49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fimmu.2012.00336","article-title":"Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3","volume":"3","author":"Moesta","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.hlc.2022.12.014_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.hlc.2022.12.014_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.hlc.2022.12.014_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.stem.2013.11.014","article-title":"An effective approach to prevent immune rejection of human ESC-derived allografts","volume":"14","author":"Rong","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.hlc.2022.12.014_bib53","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hlc.2022.12.014_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.hlc.2022.12.014_bib55","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/TP.0b013e3181f9960d","article-title":"The generation of donor-specific CD4+CD25++CD45RA+ naive regulatory T cells in operationally tolerant patients after pediatric living-donor liver transplantation","volume":"90","author":"Nafady-Hego","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.hlc.2022.12.014_bib56","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2022.12.014_bib57","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1038\/s41598-020-58126-z","article-title":"Syngeneic mesenchymal stem cells reduce immune rejection after induced pluripotent stem cell-derived allogeneic cardiomyocyte transplantation","volume":"10","author":"Yoshida","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2022.12.014_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41598-019-57088-1","article-title":"Efficient generation of thymic epithelium from induced pluripotent stem cells that prolongs allograft survival","volume":"10","author":"Otsuka","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.hlc.2022.12.014_bib59","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2492\/inflammregen.35.238","article-title":"New immune regulation strategy in the age of regenerative medicine using pluripotent stem cells","volume":"35","author":"Wada","year":"2015","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.hlc.2022.12.014_bib60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.hlc.2022.12.014_bib61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature10135","article-title":"Immunogenicity of induced pluripotent stem cells","volume":"474","author":"Zhao","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.hlc.2022.12.014_bib62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature11807","article-title":"Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells","volume":"494","author":"Araki","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.hlc.2022.12.014_bib63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.stem.2013.01.006","article-title":"Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells","volume":"12","author":"Guha","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.hlc.2022.12.014_bib64","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.stemcr.2013.08.007","article-title":"Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate","volume":"1","author":"Morizane","year":"2013","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.hlc.2022.12.014_bib65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-021-01257-1","article-title":"Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys","volume":"27","author":"Tao","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.hlc.2022.12.014_bib66","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","article-title":"Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease","volume":"382","author":"Schweitzer","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623001087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950623001087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:08:55Z","timestamp":1761415735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950623001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1443950623001087"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2022.12.014","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac Regeneration Using Pluripotent Stem Cells and Controlling Immune Responses","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2022.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}